Cervical cancer trial explores adding targeted drug to standard therapy
NCT ID NCT00957411
First seen Nov 25, 2025 · Last updated May 22, 2026 · Updated 19 times
Summary
This study tested whether adding the targeted drug cetuximab to standard radiation and chemotherapy (cisplatin) helps control cervical cancer better than radiation and cisplatin alone. It included 76 patients with stage IB2 to IIIB cervical cancer that could not be surgically removed right away. The main goal was to see if the combination improved the chance of staying cancer-free for two years.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Institut Curie Hopital
Paris, 75248, France
Conditions
Explore the condition pages connected to this study.